JPMorgan raises target for BeOne Medicines stock to USD 445.00

Published on 10/05/2026 at 12:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JPMorgan moved its target from USD 425.00 to USD 445.00 on October 1, 2026. BeOne Medicines stock costs EUR 324.00 after EUR 316.00, plus 2.53 percent.

ONC, US07725L1026, Illustration mit AI erstellt.

BeOne Medicines (ISIN US07725L1026) was trading at EUR 324.00 at Lang & Schwarz on October 5, 2026, up EUR 8.00 or 2.53 percent versus the EUR 316.00 prior close. Markets Insider reported on October 1, 2026, that JPMorgan raised its BeOne Medicines target from USD 425.00 to USD 445.00 and maintained an Overweight rating. The target is 24.28 percent above the USD 358.07 Nasdaq price recorded on October 2, 2026.

JPMorgan raises the target

The analyst action adds a fresh valuation reference after BeOne Medicines delivered a strong second quarter. The USD 20.00 increase places the new target above the average target of USD 432.80 cited by market coverage, while the stock's USD 385.22 52-week high remains a separate market benchmark as of October 2, 2026.

The target change also keeps attention on BRUKINSA, the company's leading blood-cancer medicine. Yahoo Finance reported that BRUKINSA revenue exceeded USD 1.2 billion in the second quarter of 2026, up 31.00 percent year over year.

Revenue reaches USD 1.7 billion

In the second quarter of 2026, BeOne Medicines generated USD 1.7 billion in revenue, a 30.00 percent increase from the prior-year period, according to Yahoo Finance. GAAP earnings per ADS reached USD 2.05 versus USD 0.84 in the prior-year period, while net income was USD 237.0 million.

Management also raised its 2026 revenue outlook by USD 300.0 million to USD 6.6 billion-USD 6.8 billion. That guidance range gives the JPMorgan target a fundamental backdrop, but the valuation still depends on commercial execution and the company's pipeline of oncology medicines.

Nasdaq range sets the frame

BeOne Medicines had a market capitalization of USD 38.3 billion on October 2, 2026. Its Nasdaq 52-week range was USD 253.95 to USD 385.22, and the primary-exchange quote was last at USD 358.07 on October 2, 2026 at 4:00 p.m. ET. The company operates in Healthcare and Biotechnology and develops oncology treatments for markets including the United States, China and Europe.

EUR 324.00 in afternoon trading

BeOne Medicines stock was trading at EUR 324.00 at Lang & Schwarz on October 5, 2026 at 12:36 p.m. CEST, plus 2.53 percent versus the Lang & Schwarz prior close of EUR 316.00 on October 2, 2026. The reference price is an intraday euro quote, while the Nasdaq figures provide separate U.S. market context.